<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-111801</identifier>
<setSpec>1888-4415</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Autologous concentrated bone marrow graft in the treatment of femoral head avascular necrosis: Clinical outcome after two years of follow up in a non-controlled prospective study</dc:title>
<dc:description xml:lang="en">Objective. To assess the efficacy of implanting concentrated bone marrow rich in mesenchymal stem cells (MSC) for the treatment of femoral head avascular necrosis (AVN) to prevent or delay total hip replacement (THR). Material and methods. A single-centre, prospective, non-controlled clinical study was conducted on patients with a diagnosis of AVN. The parameters assessed were, patient demographics, Harris Hip Score (HHS), imaging test (X-ray and NMR), and staging using the Arlet-Ficat scale. The patients were followed up for 1, 6, 12 and 24 months. The bone marrow was aspirated from the iliac crest, concentrated with the Harvest SmartPReP 2 system, and infused into the necrotic area by means of core decompression. Results. A total of 22 hips in 17 patients were recruited between the years 2006 to 2012, with a minimum follow-up of 2 years. A mean of 119.5mL of aspirate was extracted, with 15.25ml of MSC being implanted. During the first 2 years of the infusion, 5 hips (24.7%) required THR, with no differences in the baseline Arlet-Ficat stage, and 4 of these (80%) had femoral head involvement equal to or higher than 30%. A significant increase of 14.27 (P=.026) in the HHS and a 0.98 (P=.089) decrease in the VAS was observed two years after the infusion in the remaining 17 hips. The results suggest that the infusion of concentrated bone marrow rich in MSC, combined with surgical decompression of the nucleus, improves hip function (HHS), and avoids THR in 75.3% of patients with AVN treated during the first 2 years (AU)</dc:description>
<dc:creator>Vaquero, J</dc:creator>
<dc:creator>Cuervas-Mons, M</dc:creator>
<dc:creator>Narbona, J</dc:creator>
<dc:creator>Laguna, R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo. Evaluar la utilidad del aporte de concentrado de médula ósea rico en células troncales mesenquimales (MSC) como tratamiento de la necrosis avascular de cabeza femoral (NAV) para evitar o retrasar la artroplastia total de cadera (ATC). Material y métodos. Estudio clínico unicéntrico, prospectivo, no controlado, de pacientes con diagnóstico de NAV. Evaluación de parámetros demográficos, Harris Hip Score (HHS), pruebas de imagen (radiografía y RMN); estadificación mediante escala de Arlet-Ficat. Seguimiento a 1, 6, 12 y 24 meses. Aspirado de médula ósea de cresta ilíaca, concentrado con sistema Harvest SmartPReP 2, e infusión en zona de necrosis mediante forages. Resultados. Veintidós caderas en 17 pacientes fueron reclutados entre los años 2006-2012, seguimiento mínimo 2 años. Extracción media de 119,5ml de aspirado, implantándose 15,25ml de concentrado de MSC. Durante los primeros 2 años de la infusión 5 caderas (24,7%) precisaron ATC, sin diferencias en estadio de Ficat basal, y 4 (80%) de ellas presentaban afectación de cabeza femoral igual o superior al 30%. En las 17 caderas restantes, se observó a los 2 años de la infusión un aumento significativo del HHS (14,27) (p=0,026) y disminución del dolor (0,98) en la EVA (p=0,089). Nuestros resultados sugieren que la infusión de concentrado de médula ósea rico en MSC asociado a descompresión quirúrgica del núcleo mejora significativamente la funcionalidad de la cadera (HHS) y evita la ATC en el 75,3% de los pacientes con NAV tratados durante los primeros 2 años (AU)</dc:description>
<dc:source>Rev. esp. cir. ortop. traumatol. (Ed. impr.);57(2): 106-10, mar.-abr. 2013.</dc:source>
<dc:identifier>ibc-111801</dc:identifier>
<dc:title xml:lang="es">Implante de concentrado de médula ósea autógeno en el tratamiento de la necrosis isquémica de cabeza femoral: evolución clínica al segundo año de seguimiento de un estudio prospectivo no controlado</dc:title>
<dc:subject>^d10205^s22057</dc:subject>
<dc:subject>^d30724^s22021</dc:subject>
<dc:subject>^d10205^s22012</dc:subject>
<dc:subject>^d6778^s22016</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d30724^s22031</dc:subject>
<dc:subject>^d1731^s22074</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d36500^s22042</dc:subject>
<dc:subject>^d36500^s29166</dc:subject>
<dc:subject>^d6778^s22057</dc:subject>
<dc:subject>^d4220^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d1731^s22045</dc:subject>
<dc:subject>^d5368^s22057</dc:subject>
<dc:subject>^d5368^s22032</dc:subject>
<dc:type>article</dc:type>
<dc:date>201304</dc:date>
</metadata>
</record>
</ibecs-document>
